JP5296284B2 - 濫用阻止式オピオイド内蔵経皮的システム - Google Patents

濫用阻止式オピオイド内蔵経皮的システム Download PDF

Info

Publication number
JP5296284B2
JP5296284B2 JP2002584836A JP2002584836A JP5296284B2 JP 5296284 B2 JP5296284 B2 JP 5296284B2 JP 2002584836 A JP2002584836 A JP 2002584836A JP 2002584836 A JP2002584836 A JP 2002584836A JP 5296284 B2 JP5296284 B2 JP 5296284B2
Authority
JP
Japan
Prior art keywords
solvent
beads
dosage form
transdermal
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002584836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529155A (ja
Inventor
リノ タバレス
ブルース ライデンバーグ
リチャード サックラー
カーチス ライト
マーク エイ アルフォンソ
ベンジャミン オシュラック
ジェームス キャシディ
アンソニー イー カーパンザノ
ランパーナ プラサッド グラパリ
イホール シェブチュク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of JP2004529155A publication Critical patent/JP2004529155A/ja
Application granted granted Critical
Publication of JP5296284B2 publication Critical patent/JP5296284B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
    • B09B2101/00—Type of solid waste
    • B09B2101/65—Medical waste
    • B09B2101/68—Transdermal patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002584836A 2001-05-01 2002-04-30 濫用阻止式オピオイド内蔵経皮的システム Expired - Fee Related JP5296284B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28787501P 2001-05-01 2001-05-01
US60/287,875 2001-05-01
US29253701P 2001-05-22 2001-05-22
US60/292,537 2001-05-22
PCT/US2002/014073 WO2002087482A1 (en) 2001-05-01 2002-04-30 Abuse resistant opioid containing transdermal systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013059477A Division JP2013144702A (ja) 2001-05-01 2013-03-22 濫用阻止式オピオイド内蔵経皮的システム

Publications (2)

Publication Number Publication Date
JP2004529155A JP2004529155A (ja) 2004-09-24
JP5296284B2 true JP5296284B2 (ja) 2013-09-25

Family

ID=26964697

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002584836A Expired - Fee Related JP5296284B2 (ja) 2001-05-01 2002-04-30 濫用阻止式オピオイド内蔵経皮的システム
JP2013059477A Withdrawn JP2013144702A (ja) 2001-05-01 2013-03-22 濫用阻止式オピオイド内蔵経皮的システム
JP2014197710A Pending JP2015042649A (ja) 2001-05-01 2014-09-29 濫用阻止式オピオイド内蔵経皮的システム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013059477A Withdrawn JP2013144702A (ja) 2001-05-01 2013-03-22 濫用阻止式オピオイド内蔵経皮的システム
JP2014197710A Pending JP2015042649A (ja) 2001-05-01 2014-09-29 濫用阻止式オピオイド内蔵経皮的システム

Country Status (11)

Country Link
US (2) US20040241218A1 (https=)
EP (3) EP2062573B1 (https=)
JP (3) JP5296284B2 (https=)
AT (2) ATE533478T1 (https=)
CY (2) CY1108821T1 (https=)
DE (1) DE60230138D1 (https=)
DK (3) DK2062573T3 (https=)
ES (3) ES2318010T3 (https=)
PT (3) PT2062573E (https=)
SI (3) SI2062573T1 (https=)
WO (1) WO2002087482A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU2002339378A1 (en) 2001-05-22 2002-12-03 Euro-Celtique Compartmentalized dosage form
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
JP2005526839A (ja) * 2002-04-23 2005-09-08 アルザ・コーポレーシヨン 不正使用の可能性が低い経皮鎮痛薬システム
ES2283812T3 (es) * 2002-06-10 2007-11-01 Euro Celtique Sa Sistemas de eliminacion de dispositivos de adminsitracion transdemica para prevenir el uso indebido de los agentes activos contenidos en los mismos.
US7815934B2 (en) * 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
DE10250088A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
RS20050812A (sr) * 2003-04-30 2007-12-31 Purdue Pharma L.P., Transdermalni dozni oblik otporan na promene
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
DE602004011055T2 (de) * 2003-07-25 2008-12-18 Euro-Celtique S.A. Präoperative behandlung von postoperativen schmerzen
CA2543610A1 (en) * 2003-10-30 2005-05-19 Alza Corporation Transdermal analgesic systems having reduced abuse potential
US8535711B2 (en) 2004-01-23 2013-09-17 Teikoku Pharma Usa, Inc. Medication disposal system
US7867511B2 (en) 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
PT1718258E (pt) * 2004-02-23 2009-06-16 Euro Celtique Sa Dispositivo de administração transdérmica de opióides com resistência ao abuso
WO2006023644A2 (en) * 2004-08-20 2006-03-02 3M Innovative Properties Company Transdermal drug delivery device with translucent protective film
US7226619B1 (en) 2004-09-07 2007-06-05 Pharmorx Inc. Material for controlling diversion of medications
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
SI1814531T1 (sl) * 2004-10-21 2010-10-29 Durect Corp Transdermalni dostavni sistem
WO2006069008A1 (en) * 2004-12-22 2006-06-29 Vesta Medical, Llc Compositions and devices for inactivation of pharmaceuticals to facilitate waste disposal, and methods thereof
US20060182819A1 (en) * 2005-02-17 2006-08-17 Ough Yon D Soap scent patch and treatment for muscle spasm and pain
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
EP1898891A2 (en) * 2005-05-13 2008-03-19 Alza Corporation Multilayer drug delivery system with barrier against antagonist exposure
ATE478659T1 (de) 2005-05-13 2010-09-15 Alza Corp Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss
US20070014839A1 (en) * 2005-07-18 2007-01-18 Stefan Bracht Decomposer film for transdermal patches
US9056061B2 (en) 2005-09-23 2015-06-16 Alza Corporation Transdermal nicotine salt delivery system
US8383149B2 (en) 2005-09-23 2013-02-26 Alza Corporation High enhancer-loading polyacrylate formulation for transdermal applications
EP1968539A2 (en) * 2005-12-13 2008-09-17 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
DE102006025282A1 (de) * 2006-05-31 2007-12-20 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US20080008747A1 (en) * 2006-07-07 2008-01-10 Royds Robert B Transdermal patch
DK2054031T3 (en) 2006-07-21 2016-05-17 Biodelivery Sciences Int Inc Transmucosal delivery devices with improved uptake
WO2008063301A2 (en) * 2006-10-11 2008-05-29 Alpharma, Inc. Pharmaceutical compositions
US20080286348A1 (en) * 2007-05-16 2008-11-20 Todhunter John A Secured transdermal delivery system
DE102007041557B4 (de) * 2007-08-29 2011-03-31 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend längliche Hohlkörper
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP2011515495A (ja) * 2008-03-26 2011-05-19 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑制経皮製剤
DE102008016804B4 (de) * 2008-04-02 2012-01-05 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System mit verbesserter Funktionalität und Wirksamkeit sowie seine Verwendung
JP2013523780A (ja) * 2010-04-02 2013-06-17 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑止性経皮製剤
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
AU2012296346A1 (en) 2011-08-18 2014-04-03 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
WO2013049380A1 (en) 2011-09-30 2013-04-04 Teikoku Pharma Usa, Inc. Transdermal patch disposal system
JP2014528276A (ja) 2011-09-30 2014-10-27 テイコク ファーマ ユーエスエー インコーポレーテッド 一般用医薬品廃棄システム
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
WO2016049266A1 (en) * 2014-09-24 2016-03-31 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
WO2017147568A1 (en) * 2016-02-26 2017-08-31 Case Western Reserve University Composite membranes for flow batteries
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
WO2020008366A1 (en) * 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
WO2020009685A1 (en) * 2018-07-02 2020-01-09 John Tang Transdermal dosage form
US20210346662A1 (en) * 2018-10-23 2021-11-11 Kindeva Drug Delivery L.P. Tamper evident transdermal patch
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
CN114401746A (zh) * 2019-08-12 2022-04-26 耶路撒冷希伯来大学伊森姆研究发展有限公司 包括鸦片拮抗剂组合的药学组合物及复合材料及其使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643987A1 (de) * 1986-12-22 1988-06-23 Lohmann Therapie Syst Lts Basische, wirkstoffdurchlaessige haftklebende polymermasse, insbesondere zum einsatz mit basischen wirkstoffen, verfahren zu ihrer herstellung und ihre verwendung
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5573778A (en) * 1995-03-17 1996-11-12 Adhesives Research, Inc. Drug flux enhancer-tolerant pressure sensitive adhesive composition
WO1997004835A1 (de) * 1995-07-28 1997-02-13 Novartis Ag Transdermales system
US7011843B2 (en) * 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
CA2314896C (en) * 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
US6554851B1 (en) * 1999-05-07 2003-04-29 Scimed Life Systems, Inc. Methods of sealing an injection site
EP1424973B1 (en) * 2001-04-23 2010-03-03 Euro-Celtique S.A. Disposal system for transdermal dosage form

Also Published As

Publication number Publication date
EP1397095A4 (en) 2005-05-25
EP2316439A1 (en) 2011-05-04
ES2318010T3 (es) 2009-05-01
EP1397095A1 (en) 2004-03-17
DE60230138D1 (de) 2009-01-15
EP1397095B1 (en) 2008-12-03
EP2062573A1 (en) 2009-05-27
JP2004529155A (ja) 2004-09-24
DK1397095T3 (da) 2009-03-09
DK2316439T3 (en) 2015-08-10
SI2062573T1 (sl) 2012-02-29
US20140199383A1 (en) 2014-07-17
US20040241218A1 (en) 2004-12-02
ATE415952T1 (de) 2008-12-15
PT1397095E (pt) 2009-02-17
EP2316439B1 (en) 2015-06-17
PT2316439E (pt) 2015-08-28
JP2013144702A (ja) 2013-07-25
CY1108821T1 (el) 2014-04-09
ES2546828T3 (es) 2015-09-29
EP2062573B1 (en) 2011-11-16
JP2015042649A (ja) 2015-03-05
SI2316439T1 (sl) 2015-10-30
DK2062573T3 (da) 2012-01-30
WO2002087482A1 (en) 2002-11-07
ES2377672T3 (es) 2012-03-29
CY1112271T1 (el) 2015-12-09
ATE533478T1 (de) 2011-12-15
PT2062573E (pt) 2012-01-11
SI1397095T1 (sl) 2009-04-30

Similar Documents

Publication Publication Date Title
JP5296284B2 (ja) 濫用阻止式オピオイド内蔵経皮的システム
Lawson et al. Curcumin delivery on metal–organic frameworks: the effect of the metal center on pharmacokinetics within the M-MOF-74 family
CN101032488B (zh) 含吡罗昔康-无机材料络合物的经皮组合物及由其组成的贴片系统
CN1827107B (zh) 用丁丙诺啡实现持续止痛
AU621952B2 (en) Dosage form having reduced abuse potential
JP4526602B2 (ja) 創傷部への活性物質投与の為の薬剤形態
CN101478952A (zh) 凝胶剂形式的含罗匹尼洛的药物组合物及其应用
KR102084571B1 (ko) 경피 약물 투여 장치
AU5891999A (en) Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
Kamel et al. Double-phase hydrogel for buccal delivery of tramadol
PT1513532E (pt) Sistemas para eliminar dispositivos de veiculação transdérmica para impedir uma má utilização dos agentes activos neles contidos
AU2004261182B2 (en) Treatment of dependence withdrawal
HUP0101546A2 (hu) Opioid antagonistát és NMDA-receptor komplex modulátort tartalmazó gyógyászati készítmény alkohol- és drogfüggőség kezelésére
US7763274B2 (en) Administration form with active substance-containing particles, for application on the skin or mucosa
Sagare et al. Development, Characterization, and In‐Vitro Evaluation of Niosomal Transdermal Patch of Lamotrigine Drug
AU2021334058A1 (en) Mucosa perforation
UA83036C2 (ru) Фармацевтическая композиция в виде гидрогеля для трансдермального введения в организм действующих веществ
US20040241231A1 (en) Flat, oral dosage form comprising particles containing active ingredients
Xiao et al. Preparation and transdermal performance study of a new S‐(‐)‐nicotine‐loaded nano flexible liposome hydrogel patch with long‐lasting and sustained drug‐release effects
WO2025165825A1 (en) Topical oral compositions for scavenging drugs/toxins from saliva and methods of making and using the same
Saleem et al. Formulation and evaluation of mucoadhesive buccal tablets of sumatriptan succinate
CN115040632A (zh) 一种提高人体免疫力的抗菌药的支配方法
Chimmiri et al. Design and characterization of Buccal Films of Tramadol Hydrochloride
US20130216603A1 (en) Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
HK1085922A (en) Tiotropium containing hfc solution formulations

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100609

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100812

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100903

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20121203

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130613

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees